- SimBioSys announced it raised $15m in Series A funding to accelerate the development and commercialization of its TumorScope software platform. - The company’s novel, simulation-based, precision medicine platform enables individualized treatment planning for cancer patients. - This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic. - Existing investors and founders also participated in this financing round, bringing the company’s total capital raised to $21m. - In the first half of 2021, SimBioSys tripled its headcount, bringing in expert clinicians, scientists, and executives from the life sciences industry.

– Saama technologies announced a strategic growth investment and will be acquired by Carlyle.
– Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
– As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics.
– Carlyle has made a strategic growth investment and will acquire a majority stake in the Company.
– A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

– Emulate, Inc. announced the close of an $82m Series E financing round.
– The round was led by Northpond Ventures with additional participation from Perceptive Advisors.
– With this investment, Emulate has raised nearly $225m to date.
– Emulate develops and manufactures next-generation in vitro models that enable researchers to replicate and study human biology and disease, helping them understand and predict drug response with greater precision and detail than possible with conventional cell culture or animal-based methods.
– Organ-on-a-chip technology by Emulate provides flexible microenvironments containing tiny hollow channels lined with living cells and tissues that can be subjected to mechanical forces that mirror breathing or digestion in the human body.

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

– Slingshot Biosciences closed a $23m Series A financing.
– The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital.
– The new funding will enable Slingshot to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies.
– Adam Wieschhaus, PhD, Director at Northpond Ventures, and Corey Ritter, Senior Associate at ARCH Venture Partners, will join the Board of Directors.
– Slingshot will also invest heavily in its broader adoptive cell therapy and therapeutics platform with this growth financing.
– Cell-derived products comprise the basis of important healthcare technologies worldwide.

– CAMP4 Therapeutics announced that it has raised $45m to propel the next phase of its scientific strategy, significantly expand its platform and advance multiple preclinical RNA therapies into human testing.
– CAMP4 is combining its proprietary RNA Actuating Platform (RAP) with state-of-the-art oligonucleotide technology to develop precise and programmable therapeutics that enable tunable upregulation of gene expression to treat disease.
– CAMP4’s approach uniquely targets a new class of RNA known as regulatory RNAs (“regRNAs”) that control the expression of proteins, making this approach applicable to any genetic disease whereby a small increase in gene output can lead to meaningful therapeutic outcomes.
– 5AM Ventures and Northpond Ventures led the financing alongside existing investors Andreessen Horowitz, Polaris Partners and The Kraft Group.

– Hawthorne Effect, a San Francisco CA-based company which offers solutions for decentralizing clinical trials, raised $20M in Series A funding.
– The round was led by Northpond Ventures, with participation from SignalFire and P5 Health Ventures.
– The company intends to use the funds to accelerate growth and help scale operations.

– Torus Biosystems announced the completion of a $25m Series A financing.
– The round was led by Northpond Ventures with participation from prior investors including David Walt, PhD, a professor at Harvard Medical School and Torus Bio cofounder and board observer.
– Funding proceeds will be used to accelerate commercialization of a first-in-class syndromic testing solution designed for point-of-care use in ambulatory care settings.
– The company is developing a compact and fully automated system offering the advantages of rapid detection, from sample-to-result in less than 30 minutes, of a wide variety of microorganisms and antibiotic resistance markers.

– Ultivue announced the completion of a $50m Series D round of financing.
– New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners.
– Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.
– This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.

– Current Health – the leading enterprise remote care management platform – announced it has raised $43M in Series B financing.
– The round was led by Northpond Ventures, with additional financing from LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures, and existing investors.
– Andrea Jackson, Director at Northpond Ventures, and Tripp Peake, General Partner at LRVHealth, will join Current Health’s Board of Directors.
– The Series B financing, which comes from top healthcare and pharma VCs, as well as a leading hospital system, speaks to the value of Current Health’s platform across a broad array of stakeholders.

– Vizgen from Cambridge, MA develops genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease with spatial context.
– Series B $37m round was led by Novalis LifeSciences LLC and current investor Northpond Ventures with participation from new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund, and current investors ARCH Venture Partners and David Walt, Ph.D., Professor at Harvard Medical School, Core Faculty at the Wyss Institute, and co-founder of Vizgen.
– The company intends to use the funds to accelerate growth and infrastructure expansion leading up to full commercial launch.

– Scipher Medicine completed an $82m Series C funding.
– The round was led by aMoon and Northpond Ventures, with participation from Echo Health Ventures and existing investors, Khosla Ventures and Alumni Ventures.
– The new funding will be used to expand commercial efforts for its patient molecular signature test, PrismRA.

– Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102m Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio.
– D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures.
– Sepsis caused more than five million deaths annually worldwide before the COVID-19 pandemic, and severe COVID-19 has been recognized as viral sepsis. In addition, antibiotic resistance is directly responsible for more than 700,000 deaths annually worldwide.

– StrideBio, Inc. is a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies.
– The company closed a $81.5m Series B funding round.
– Northpond Ventures and Novo Holdings A/S co-led the round with new investors Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and UF Innovate Ventures joining existing investors Hatteras Venture Partners, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.